Health-related quality of life (HRQL) in VERTU: A randomized phase II trial of veliparib (V), radiotherapy (RT), and temozolomide (TMZ) for newly diagnosed MGMT unmethylated (uMGMT) glioblastoma (GBM).

被引：1
|
作者：
Sim, Hao-Wen
Barnes, Elizabeth
Lwin, Zarnie
Rosenthal, Mark
Wheeler, Helen
Koh, Eng-Siew
Foote, Matthew C.
Fisher, Lauren
Leonard, Robyn
Hall, Merryn
Simes, John
Khasraw, Mustafa
机构：
[1] St Vincents Hosp Sydney, Kinghorn Canc Ctr, Sydney, NSW, Australia
[2] Univ Sydney, NHMRC Clin Trials Ctr, Camperdown, NSW, Australia
[3] Dept Med Oncol, Brisbane, Qld, Australia
[4] Royal Melbourne Hosp, Parkville, Vic, Australia
[5] Royal North Shore Hosp, Dept Oncol, St Leonards, NSW, Australia
[6] Liverpool Hosp, Liverpool, Merseyside, Australia
[7] Univ Queensland, Princess Alexandra Hosp, Brisbane, Qld, Australia
[8] NHMRC Clin Trials Ctr, Sydney, NSW, Australia
[9] COGNO Consumer Advisory Panel, Sydney, NSW, Australia
[10] Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW, Australia
[11] Univ Sydney, Royal North Shore Hosp, St Leonards, NSW, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.2042
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2042
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM).
    Omuro, A. A.
    Beal, K.
    Karimi, S.
    Chan, T. A.
    Panageas, K.
    Nayak, L.
    Seko, B.
    DeAngelis, L. M.
    Abrey, L. E.
    Gutin, P. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [22] Nivolumab (nivo) in combination with radiotherapy (RT) ± temozolomide (TMZ): Updated safety results from CheckMate 143 in pts with methylated or unmethylated newly diagnosed glioblastoma (GBM)
    Lim, M.
    Omuro, A.
    Vlahovic, G.
    Reardon, D. A.
    Sahebjam, S.
    Cloughesy, T.
    Baehring, J.
    Butowski, N.
    Potter, V.
    Zwirtes, R.
    Paliwal, P.
    Carleton, M.
    Sampson, J.
    Brandes, A. A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [23] A randomized phase II trial of concurrent temozolomide (TMZ) and radiotherapy (RT) followed by dose-dense compared to metronomic TMZ and maintenance cis-retinoic acid for patients with newly diagnosed glioblastoma multiforme (GBM)
    Clarke, Jennifer
    Sul, Joohee
    DeAngelis, Lisa
    Lassman, Andrew
    Hormigo, Adilia
    Nolan, Craig
    Gavrilovic, Igor
    Gu, Bin
    Panageas, Kathy
    Abrey, Lauren
    NEURO-ONCOLOGY, 2007, 9 (04) : 530 - 530
  • [24] Phase I adult brain tumor consortium (ARTC) trial of ABT-888 (veliparib), temozolomide (TMZ), and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM) including pharmacokinetic (PK) data
    Kleinberg, Lawrence
    Supko, Jeffrey G.
    Mikkelsen, Tom
    Blakeley, Jaishri O'Neill
    Stevens, Glen
    Ye, Xiaobu
    Desideri, Serena
    Ryu, Samuel
    Desai, Bhardwaj
    Giranda, Vincent L.
    Grossman, Stuart A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [25] Progression-free survival (PFS) and health-related quality of life (HRQoL) in AVAglio, a phase III study of bevacizumab (Bv), temozolomide (T), and radiotherapy (RT) in newly diagnosed glioblastoma (GBM)
    Henriksson, Roger
    Bottomley, Andrew
    Mason, Warren
    Saran, Frank
    Wick, Wolfgang
    Nishikawa, Ryo
    Cloughesy, Timothy Francis
    Carpentier, Antoine F.
    Khe Hoang-Xuan
    Kavan, Petr
    Cernea, Dana
    Brandes, Alba Ariela
    Hilton, Magalie
    Guijarro, Ana Maria Abajo
    Ravelo, Arliene
    Chinot, Oliver L.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [26] HEALTH-RELATED QUALITY OF LIFE (HRQOL) ANALYSES IN THE AVAGLIO STUDY, A RANDOMIZED, PLACEBO-CONTROLLED PHASE III TRIAL OF BEVACIZUMAB, TEMOZOLOMIDE AND RADIOTHERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA
    Taphoorn, Martin J. B.
    Henriksson, Roger
    Bottomley, Andrew
    Cloughesy, Timothy
    Wick, Wolfgang
    Mason, Warren
    Saran, Frank
    Nishikawa, Ryo
    Ravelo, Arliene
    Hilton, Magalie
    Chinot, Olivier L.
    NEURO-ONCOLOGY, 2013, 15 : 232 - 232
  • [27] Concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM). Conclusive results of a randomized phase III trial by the EORTC Brain & RT Groups and NCIC Clinical Trials Group
    Stupp, R
    Mason, WP
    Van Den Bent, MJ
    Weller, M
    Fisher, B
    Taphoorn, M
    Brandes, AA
    Cairncross, G
    Lacombe, D
    Mirimanoff, RO
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 1S - 1S
  • [28] AN AMERICAN BRAIN TUMOR CONSORTIUM (ABTC) PHASE I TRIAL OF ABT-888 (VELIPARIB), TEMOZOLOMIDE (TMZ), AND CONCURRENT RADIOTHERAPY (RT) FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM): HEMATOLOGIC TOXICITY IS LIMITING.
    Kleinberg, Lawrence
    Blakeley, Jaishri
    Mikkelsen, Tom
    Stevens, Glenn
    Ye, Xiaobu
    Ryu, Sam
    Desideri, Serena
    Desai, Bhardwaj
    Giranda, Vincent
    Grossman, Stuart
    NEURO-ONCOLOGY, 2012, 14 : 102 - 102
  • [29] Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial)
    Supriya Mallick
    Haresh Kunhiparambath
    Subhash Gupta
    Rony Benson
    Seema Sharma
    M. A. Laviraj
    Ashish Datt Upadhyay
    Pramod Kumar Julka
    Dayanand Sharma
    Goura Kishor Rath
    Journal of Neuro-Oncology, 2018, 140 : 75 - 82
  • [30] Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial)
    Mallick, Supriya
    Kunhiparambath, Haresh
    Gupta, Subhash
    Benson, Rony
    Sharma, Seema
    Laviraj, M. A.
    Upadhyay, Ashish Datt
    Julka, Pramod Kumar
    Sharma, Dayanand
    Rath, Goura Kishor
    JOURNAL OF NEURO-ONCOLOGY, 2018, 140 (01) : 75 - 82
12345